E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Aplastic anemia (AA) is a condition that occurs when your body stops producing enough new blood cells |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002967 |
E.1.2 | Term | Aplastic anaemia |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002968 |
E.1.2 | Term | Aplastic anaemia, unspecified |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10083893 |
E.1.2 | Term | Acquired aplastic anaemia |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10032510 |
E.1.2 | Term | Other specified aplastic anaemias |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002969 |
E.1.2 | Term | Aplastic anemia |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002037 |
E.1.2 | Term | Anaemia aplastic |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002274 |
E.1.2 | Term | Anemia aplastic |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Arm 1: evaluate the efficacy of romiplostim and immunosuppressive therapy (IST) in adult non Asian severe aplastic anemia (SAA) subjects who are previously untreated with IST (1L)
• Arm 2: evaluate the efficacy of romiplostim treatment in adult non Asian SAA subjects who are refractory to IST (2L+)
|
|
E.2.2 | Secondary objectives of the trial |
• Arm 1: Describe efficacy for adult non-Asian SAA subjects who are previously untreated with IST (1L) to achieve a complete response (CR) or partial response (PR) following treatment with romiplostim and IST
• Describe efficacy for non-Asian adult SAA subjects treated on the 2 study arms (1L/2L+) for decreasing the frequency of platelet and/or red blood cell (RBC) transfusions, or becoming platelet and/or RBC transfusion independent
• Assess overall safety of romiplostim treatment for non-Asian subjects treated on the 2 study arms (1L/2L+)
• Evaluate the bleeding status from baseline to week 14 in adult non-Asian SAA subjects in the 2 study arms (1L/2L+)
• Evaluate the pharmacokinetics (PK) of romiplostim when it is administered subcutaneously (SC) in adult non-Asian SAA subjects in the 2 study arms (1L/2L+)
• Evaluate the immunogenicity of romiplostim when it is administered SC in adult non-Asian SAA subjects in the 2 study arms (1L/2L+)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject has provided informed consent prior to initiation of any study specific activities/procedures or subject’s legally authorized representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator may compromise the ability of the subject to give written informed consent.
2. Age more than or equal to 18 years at time of enrollment
3. Diagnosis of severe AA or very severe AA confirmed by blood, bone marrow, and cytogenetic studies
4. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1 at screening
5. Arm 1 only: considered to require new treatment with antithymocyte globulin and CsA
6. Arm 2 only: refractory to at least 1 course of IST including horse or rabbit antithymocyte globulin; or ineligible for antithymocyte globulin treatment and refractory to CsA
7. Arm 2 only: thrombocytopenia defined as a platelet count of less than equal to 30 x 10⁹/L
|
|
E.4 | Principal exclusion criteria |
Disease-Related:
1. Diagnosed as having congenital AA (Fanconi anemia, congenital dyskeratosis, etc,)
Other Medical Conditions:
2. History of other malignancy within the past 5 years, with the exceptions detailed in protocol
3. Aplastic anemia with hemolytic paroxysmal nocturnal hemoglobinuria (hemolytic predominant is defined as lactate dehydrogenase [LDH] > 1.5 x the upper limit of site normal)
4. Diagnosed as having acute myeloblastic leukemia (AML) or chronic myelomonocytic leukemia
5. Concurrent thrombocytopenia of other etiologies (eg, MDS, ITP, cirrhosis)
6. Current or past history of arterial or venous thrombus within 1 year prior to consent
7. Concurrent active infection not adequately responding to appropriate therapy
8. Current or past history of hypersensitivity to recombinant Escherichia coli-derived proteins
9. Having grade 2 or higher bone marrow reticulin
10. Positive for anti-human immunodeficiency virus (HIV) antibody at screening
11. Receiving prophylactic or therapeutic treatment for hepatitis type B at screening
examination (excluding prophylactic treatment for initiation of antithymocyte globulin treatment), or meeting any of the following items and having active hepatitis type B infection at screening:
• Positive for hepatitis B surface antigen (HBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B).
• Negative HBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA suggests occult hepatitis B.
If any of the hepatitis B virus tests has an indeterminate result, confirmatory testing will be performed by an alternative method that is locally accepted.
12. Positive hepatitis C virus antibody (HCVAb): hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C.
Prior/Concomitant Therapy:
13. Arm 1 only: Previously treated with antithymocyte globulin, CsA, or Alemtuzumab
14. Previously treated with PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human TPO, romiplostim and other TPO-receptor agonist (eltrombopag, etc,)
15. Planned HSCT during the study
16. Systemic treatment with any of the following medication for the treatment of AA within 4 weeks before day 1, however, excluding their use as premedication:
• anabolic steroids
• corticosteroids
Prior/Concurrent Clinical Study Experience:
17. Currently receiving treatment in another investigational device or drug study, or less than 16 weeks (or 5-fold of the half-life [whichever is longer]) since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
Diagnostic Assessments:
18. Having blast cells > 2% in bone marrow at screening;
19. Any of the following laboratory abnormalities at screening:
• Total bilirubin (TBL): ≥ 1.5 times the upper limit of site normal
• ALT: ≥ 3.0 times the upper limit of site normal
• Aspartate aminotransferase (AST): ≥ 3.0 times the upper limit of site normal
• Creatinine: > 2.0 mg/dL
• Other abnormal laboratory values that are considered by the investigator to affect the completion of the study or evaluations
20. History of chromosome aberrations discovered in bone marrow cells within 12 weeks prior to day 1. If the sponsor’s medical expert judged not to be problematic participation in this study, the patient can be enrolled.
Other Exclusions:
21 Subjects with Asian ethnicity defined as persons having origins in any of the original peoples of the Far East and Southeast Asia.
22 Female subjects of childbearing potential unwilling to use protocol specified method of contraception , during treatment and until 3 months after investigational product(s) treatment.
23 Female subjects who are breastfeeding or who plan to breastfeed while on study through 3 months after investigational product(s) treatment.
24 Female subjects planning to become pregnant while on study through 3 months after investigational product(s) treatment.
25 Female subjects of childbearing potential with a positive pregnancy test assessed at Screening by a highly sensitive serum pregnancy test.
26 Subject has known sensitivity to any of the products or components to be administered during dosing.
27 Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator’s knowledge.
28 History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.3.1 | Comparator description |
Cyclosporine A and Horse or Rabbit ATG |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
United States |
France |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 26 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 26 |